{"name":"Beta Pharma Shanghai","slug":"beta-pharma-shanghai","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BPI-7711","genericName":"BPI-7711","slug":"bpi-7711","indication":"FGFR-altered solid tumors (including cholangiocarcinoma and other FGFR-driven cancers)","status":"phase_3"}]}],"pipeline":[{"name":"BPI-7711","genericName":"BPI-7711","slug":"bpi-7711","phase":"phase_3","mechanism":"BPI-7711 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-altered solid tumors (including cholangiocarcinoma and other FGFR-driven cancers)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"trial","source":"The Manila Times","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - The Manila Times","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFBLLXpVeUZabXFOZWNGdzl1djB2MHRpVnpNVTBRY212cE1jdmMtWGpabHJ1MVZWXzVUSkNIOHhObkc3V2drQm1oaW8yN2psVWQxWVhaYVBuZ0tkRmNmSlE?oc=5","date":"2026-03-31","type":"trial","source":"Science Partner Journals","summary":"Rezivertinib in EGFR -Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study - Science Partner Journals","headline":"Rezivertinib in EGFR -Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervou","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPSUZfRDJ0TDdudl9hVWo5aF9qcGNRd0xLeDVWMlg3TkRiUWROd0JPSm9KQmdsTlA4a3NzNGMta0ItN0Ztc2JsU2I0Um5kMU1hX2RSQ3lmVHpJRGx6RHZGajltbDN6Ujc5bUNYc3dIa3N3OTZudEJHTGg1WU5fejFpY0NjMHVOTUFlLWFqbWQ3U2IyTFRNOTVB?oc=5","date":"2026-02-10","type":"trial","source":"Endpoints News","summary":"Shanghai’s Cascade gets $72M to pursue MASH, obesity and diabetes drugs - Endpoints News","headline":"Shanghai’s Cascade gets $72M to pursue MASH, obesity and diabetes drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOVWZ3eEpJaWU4bGhKUjE5d1BtcjdaSHlacVk3UkxzQ053bDhHYnE5eVNGdEptZUpaZzNZWXNLOG80SkNWdGZENkFJc0pIdElwM1F3LUI3blh0bHpJVEh3VnRKYkFwX1p0YzF6aGpnSTZfX21vZVhLaWd3RFNaNllKSUQ4X2UzaDNkeDAyUnpzVWtjblZrLU9kTXpGcm83cS02M2tVYlF0V19XX3lMZDNKR0hqY3NhNGhVbEt1czc2M2wtNThGRVY5V0pwelI3aTQ?oc=5","date":"2025-10-17","type":"pipeline","source":"NutraIngredients.com","summary":"Sirio Pharma sets up longevity lab in Shanghai, products to launch later this year - NutraIngredients.com","headline":"Sirio Pharma sets up longevity lab in Shanghai, products to launch later this year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxQTWE5bUN3RXk0aDJSUmFRSVFJYkdYemFGc21xY2VKYWZvYzBGZUtfejQwdXdsaWc4NVhYRHBhaWt6SDJILTJwTi1aamRqeHZkUkhMNThnbzViU3FFelNuRktzYWpjOHNMNHJkRzYyTjdmekh1U2paeVNfa25hOHNCeGVvY3U2OURreXdhMHVwclNKM1ZWR2k2Q1BLRHd2QTdxcXNQWkRsdW5fd3dfOGkyUXpvZk9JRGNwWV9HNjNnMTlObWlDZU1WV25EN29XMGN6UTJQUzV2XzloQ2FuX203b1RDVGotdGpYb3FnOFN3M25jR25ITkRmd2cxY3o3dGx1cFN5WFJFb0xXdFQ0OEU3VFZsZUxCTXdoYjVvVFh0TUxRQWpuQXVONU9YQURJWlJF?oc=5","date":"2025-09-23","type":"trial","source":"GlobeNewswire","summary":"TGF-β Inhibitors Clinical Trial Pipeline Accelerates as 25+ - GlobeNewswire","headline":"TGF-β Inhibitors Clinical Trial Pipeline Accelerates as 25+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNY1JaSEFaVnFfU1RFUF85NFdPTWVkNWpVR1V5dXIxSnZiUGZZV0w2andLOEdNSXUza3FUbnl2N1dQZThDYTZ0eXV0a2V3c1JSMjJqek5aNzd1MGY1M1JkNmZreDJ3cWpRTXR4aWZTLXF1cEowS0xoMnJla3NSd1BReEhORDNmRmI5U1djd3lwNDB0UG5kM0ZzMmNxXzJpSE9YNXRyWnVuOFVDb09Ocld3djFIZF9qd2RweUNPeE5xWlVxWlZUdXUwMGlKdUg5NXVsa1E?oc=5","date":"2025-07-30","type":"pipeline","source":"PR Newswire","summary":"THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight - PR Newswire","headline":"THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPWmV0QkYyMUlGdUVkamJhMTF6d2Q2ak1FNlUtcUN4anVzZTRmd2lFa1VrRkhMTkdkNG11bUxrNjZ3TnBPak5ROFhQNGFucGhTT05KUTNld3JsNWdhVUtYVTRoWGhqcjZqZHF0WnZ5NTF4bmczM3FnM0pTU0tpb3ZVTGtyT3F1bnJkR2tYRnRpZFRvVUdmSVpZcVgzS1dsOUdiZ2o2Y3h4U04?oc=5","date":"2025-07-24","type":"pipeline","source":"International Finance Corporation (IFC)","summary":"Answering Africa’s Call for Private Investment in Pharma Manufacturing - International Finance Corporation (IFC)","headline":"Answering Africa’s Call for Private Investment in Pharma Manufacturing - International Finance Corporation (IFC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOMGRzdm5GOVV0Nk9YTXI1X3V5SUJaT2puUWRVQ2JrMTFZSFRNcmZCQlN0RmFKOHZfZ1Yxby1QVm1HT3NTNVE5X0gzTGpsMTduVW1GektSQWFrTWRsR0E3RVllY21ZbmpjcUF4NnQxSTVSRjFxbFhQbV9vVXU2RjlpVDdVUlNOZw?oc=5","date":"2025-03-25","type":"pipeline","source":"Contract Pharma","summary":"BioDuro Opens New Lab in Shanghai - Contract Pharma","headline":"BioDuro Opens New Lab in Shanghai","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQRjRubmRVT19PVEtvc0ZzVF9PaElyWDlVYTlxRUdGbmZMN2s1XzdUajNPLU1Galp6ZEZtamVWRDA2Ul9TcHR2TllEQmFXWWgybkxLRkRNS083Umdxb1k0X3F0WlBabHNuYmZYdUJUSzZZNlFadkNWSDlKaEx2ZHAtN3J0bmc4Z2oyaE5Bc2IzVnVab1cya3BPdFRadlBWRThPRGtsRFdRT1VxV3QxeHNSanNqcDc?oc=5","date":"2025-01-01","type":"pipeline","source":"bloomberg.com","summary":"Li Ka-Shing-Backed Hutchmed Sells Stake in Unit for $608 Million - bloomberg.com","headline":"Li Ka-Shing-Backed Hutchmed Sells Stake in Unit for $608 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOdTVrYVF2c0UteUw2SHZYZ05QUGZlR3VLRnhkRXFkMGZmSURVcWlweS1vdlFWQUJyU053WFZ6VzhDQjVFUzFlV0pJdkZoeGJHdkdkeHpRX0pjaW9vM2ZZWG9mdzFwRVBoUUtqUGJYeWFHUmNhVVNvdU9aNzB2N3BtVkFIWXVzVnF4dG5zUnctSnBPNVRVUm5hV2gxR2x1dlRaaVhVeFpTd2FQMWJ5MXhUUGZzRDQ1VDlNc0E?oc=5","date":"2024-04-11","type":"pipeline","source":"Fierce Pharma","summary":"89bio lines up China CDMO to build API plant for commercial production of MASH candidate - Fierce Pharma","headline":"89bio lines up China CDMO to build API plant for commercial production of MASH candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNTTVWMkRQdDZCWmNvai1lamNmWm81SlBzNV96QXU3R3VzRnpfZ3MzWGVPT3VoU2tpV1RSQlNVWDUxTVR5SUhtWFVYNmk1YVRBdTVOYldXT0FrNEd2ckREdzV6RDBxckttQUVlWloyRjJYRUkzek12ZmFVeGRGemJIVE1B?oc=5","date":"2016-06-02","type":"pipeline","source":"BioPharma Dive","summary":"With eye to growing Chinese market, Novartis opens major R&D hub in Shanghai - BioPharma Dive","headline":"With eye to growing Chinese market, Novartis opens major R&D hub in Shanghai","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}